BioXcel Therapeutics, Inc. (BTAI): Price and Financial Metrics
GET POWR RATINGS... FREE!
BTAI Stock Price Chart Interactive Chart >
BTAI Price/Volume Stats
|Current price||$37.11||52-week high||$71.50|
|Prev. close||$37.51||52-week low||$28.00|
|Day high||$37.46||Avg. volume||460,701|
|50-day MA||$34.11||Dividend yield||N/A|
|200-day MA||$44.79||Market Cap||914.09M|
BioXcel Therapeutics, Inc. (BTAI) Company Bio
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is based in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
BTAI Latest News Stream
|Loading, please wait...|
BTAI Latest Social Stream
View Full BTAI Social Stream
Latest BTAI News From Around the Web
Below are the latest news stories about BioXcel Therapeutics Inc that investors may wish to consider to help them evaluate BTAI as an investment opportunity.
Within the last quarter, BioXcel Therapeutics (NASDAQ: BTAI ) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 1 1 3 Somewhat Bullish 0 0 0 0 Indifferent 0 0 0 0 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 In the last 3 months, 6 analysts have offered 12-month price targets for BioXcel Therapeutics. The company has an average price target of $136.33 with a high of $176.00 and a low of $75.00. This current average represents a 13.72% increase from the previous average price target of $158.0. What Are Analyst Ratings? Ratings come Full story available on Benzinga.com
Photo by Design Cells/iStock via Getty ImagesI covered BioXcel Therapeutics (BTAI) last year when it was yet to submit an NDA for its lead program. This was for sublingual formulation of dexmedetomidine ((DEX)), a selective alpha-2 adrenergic receptor agonist, targeting acute agitation in schizophrenia/bipolar patients. The molecule obtained primary endpoints...
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BioXcel, will participate in fireside chats at three upcoming virtual healthcare investor conferences.
BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II
FDA sets PDUFA action date for January 5, 2022 If approved, BXCL501 would represent the first major advancement in the acute treatment of agitation associated with schizophrenia and bipolar disorders in almost a decade
BioXcel Therapeutics (NASDAQ:BTAI) had its target price reduced by HC Wainwright from $175.00 to $170.00 in a research report report published on Tuesday morning, PriceTargets.com reports. HC Wainwright currently has a buy rating on the stock. A number of other brokerages have also recently weighed in on BTAI. Canaccord Genuity cut their price objective on 
BTAI Price Returns